Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics announces a significant expansion in manufacturing capacity, increasing from 400,000 liters to 600,000 liters, enhancing its potential peak revenues to exceed $300 million. The FDA has approved the company’s expanded manufacturing process for intravenous immune globulin (IVIG), which is expected to enhance gross margins and operational efficiencies starting late 2021 and throughout 2022. This expansion allows ADMA to produce IVIG using a 4,400-liter plasma pool, confirming its position in the market and paving the way for consistent revenue growth.
ADMA Biologics, Inc. (NASDAQ: ADMA) announced the opening of its new plasma collection facility in Goose Creek, South Carolina, marking a significant expansion in its operations. Governor Henry McMaster participated in the ribbon-cutting ceremony, highlighting South Carolina's favorable environment for plasma collection. ADMA aims to have 10 or more facilities operational by 2024 to meet growing plasma demand. The new facility will enhance ADMA's self-sufficient plasma supply chain and support revenue growth. A Biologics License Application (BLA) is expected to be filed in three months.
ADMA Biologics presented a poster at the 2021 Academy of Managed Care Pharmacy Annual Meeting, emphasizing the substantial healthcare costs associated with Hepatitis B Virus (HBV) and its higher transmission risk compared to HIV. The analysis advocates for aligning CDC treatment guidelines for sexual assault victims exposed to HBV with those for HIV. The proposed intervention involves using Nabi-HB, a hyperimmune globulin, to provide cost-effective prophylaxis. CEO Adam Grossman urges policymakers to address this unmet patient need to mitigate clinical and financial consequences for the healthcare system.
ADMA Biologics reported a full year 2020 revenue of $42.2 million, marking a 44% increase from 2019. The company anticipates revenues of $250 million or more by 2024, driven by expanded plasma collection centers and improved product offerings. Despite revenue growth, ADMA faced a consolidated net loss of $75.7 million, an increase attributed to higher operational costs and investments in commercialization. The firm successfully expanded its plasma collection network and expects significant operational efficiencies with FDA approvals mid-year.
ADMA Biologics will report its financial results for Q4 and full year 2020 on March 25, 2021, after market close. The executive team will host a conference call at 4:30 p.m. ET to discuss these results, along with updates on the company's operations and products. ADMA produces FDA-approved plasma-derived biologics aimed at treating immunodeficient patients. The conference call can be accessed by dialing the provided numbers or via a live audio webcast on the company's investor website.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Jefferies Virtual Plasma Summit on March 11, 2021, at 11:20 a.m. ET. Interested parties can view the event via a webcast on the company’s website, which will be archived for 90 days post-event. The company specializes in manufacturing and marketing FDA-approved plasma-derived biologics aimed at treating immunodeficient patients and preventing infectious diseases. ADMA's key products include BIVIGAM®, ASCENIV™, and NABI-HB®.
ADMA Biologics, Inc. (NASDAQ: ADMA) has received approval from the Korean Ministry of Food and Drug Safety for its Kennesaw, Georgia plasma collection center to sell source plasma in South Korea. This approval, alongside FDA approval for a Hepatitis B immunization program at the center, marks a significant regulatory milestone for ADMA. These advancements align with ADMA's strategy to enhance its global presence and secure its supply chain for plasma-derived biologics, aimed at treating immune deficiencies and infectious diseases.
ADMA Biologics highlights a poster presentation at the AAAAI 2021 Conference, showcasing a potential polyclonal hyperimmune globulin targeting S. pneumoniae. This therapy aims to improve clinical outcomes for immune-compromised patients, bridging the gap between vaccination and seroconversion. CEO Adam Grossman emphasized the importance of addressing infection risks despite existing vaccines. The company holds patents related to this hyperimmune globulin, aiming to expand its product pipeline for underserved patient populations.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 1, 2021, at 10:50 a.m. ET. The event will be available via webcast on the company’s website and will be archived for 90 days. ADMA focuses on manufacturing and developing specialty plasma-derived biologics, with three FDA-approved products aimed at treating immunodeficient patients and preventing infectious diseases.
ADMA Biologics, Inc. (NASDAQ: ADMA) has received FDA approval for its ADMA BioCenters plasma collection facility in Knoxville, Tennessee, which began operations in Q3 2020. This approval enhances the company's raw material supply chain and manufacturing control. ADMA aims to open up to ten plasma collection centers by 2024. The facility uses state-of-the-art equipment and employs 50 trained healthcare workers. This milestone is expected to improve product yields and margins, positioning ADMA for future growth and profitability.
FAQ
What is the current stock price of Adma Biologics (ADMA)?
What is the market cap of Adma Biologics (ADMA)?
